A Major Investment in Stargardt Disease Research

According to reports from AllSci, Tarsus Pharmaceuticals has entered into an agreement to acquire Alkeus Pharmaceuticals in a transaction valued at up to USD 800 million. For the inherited retinal disease (IRD) community, this development represents a significant corporate and clinical investment focusing on Stargardt disease, a rare inherited retinal disorder currently lacking an FDA-approved treatment.

Key Deal Terms and Clinical Pipeline Focus

Under the terms of the agreement, Tarsus will pay approximately USD 450 million upfront, which consists of USD 270 million in cash and USD 180 million in Tarsus common stock. Additionally, former Alkeus shareholders are eligible for up to USD 350 million in contingent milestones tied to regulatory approval and first commercial sale, alongside low single-digit tiered royalties.

The core asset changing hands is gildeuretinol (ALK-001), a once-daily oral small molecule designed to reduce the accumulation of toxic vitamin A dimers while preserving the normal visual cycle. Gildeuretinol is currently being evaluated in Phase III development via the ongoing NORTHSTAR trial for Stargardt disease, which impacts thousands of diagnosed patients in the United States.

What This Means for Patients and Families

Stargardt disease leads to progressive and irreversible central vision loss due to genetic mutations affecting retinal cells. Because there are currently no approved therapies available on the market for patients, late-stage clinical programs like gildeuretinol are closely watched by individuals and families navigating the condition. Clinical evaluations to date have focused on measuring atrophic lesion growth and assessing visual function parameters such as low-light visual acuity.

Looking Ahead

As Tarsus builds out its broader retina portfolio—marking its second ophthalmic acquisition in a short timeframe—the clinical development timeline remains a focal point. According to study projections, topline data from the Phase III NORTHSTAR trial for gildeuretinol are anticipated in the second half of 2029.